Anxiolytic-like Effects of Dichloromethane Extracts of Valerian (DEV) in Adult Male Wistar Rats

Authors: Hadjikhani R.

Abstract:

Anxiety is a common disorder that attacks many people in society and often accompanied by physiological sensations such as tachycardia, chest pain, shortness of breath, insensitivity and etc. The purpose of this study is to characterize the putative anxiolytic-like effects of DEV (dichloromethane extracts of valerian) using the elevated plus maze (EPM) in rats. DEV was dissolved in DMSO and orally administered at different doses to adult male wistar rats, 0.5, 1.5 and 3 hours before behavioral evaluation in an EPM respectively. Control rats were treated with an equal volume of DMSO. Single treatment of DEV (at 0.1,0.2. 0.3, and 0.4 g/kg) significantly increased time-spent and arm entries into open arms of EPM versus control groups (p<0.05).However, no changes in the locomotor activity ccured. This result suggests that DEV might prove to be an effective anxiolytic agent.

Keywords: Anxiety, Dichloromethane extracts, Valerian, Rat

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1083405

References:

[1] S. Mora, R. Millan, H. Lungenstrass, G. Diaz-Veliz, J.A. Moran, M. Herrera-Ruiz, and J. Tortoriello, The hydroalcoholic extract of Salvia elegans induces anxiolytic- and antidepressant-like effects in rats. J Ethnopharmacol 106 (2006) 76-81.
[2] W.H. Peng, M.T. Hsieh, Y.S. Lee, Y.C. Lin, and J. Liao, Anxiolytic effect of seed of Ziziphus jujuba in mouse models of anxiety. J Ethnopharmacol 72 (2000) 435-41.
[3] A. Rex, E. Morgenstern, and H. Fink, Anxiolytic-like effects of kavakava in the elevated plus maze test--a comparison with diazepam. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 855-60.
[4] F. Donath, S. Quispe, K. Diefenbach, A. Maurer, I. Fietze, and I. Roots, Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 33 (2000) 47-53.
[5] B.R. Ballinger, New drugs. Hypnotics and anxiolytics. Bmj 300 (1990) 456-8.
[6] G. Beaubrun, and G.E. Gray, A review of herbal medicines for psychiatric disorders. Psychiatr Serv 51 (2000) 1130-4.
[7] W. Hui-lian, Z. Dong-fang, L. Zhao-feng, L. Yang, L. Qian-rong, and W. Yu-zhen, In vitro study on the genotoxicity of dichloromethane extracts of valerian (DEV) in human endothelial ECV304 cells and the effect of vitamins E and C in attenuating the DEV-induced DNA damages. Toxicol Appl Pharmacol 188 (2003) 36-41.
[8] H. Schulz, C. Stolz, and J. Muller, The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry 27 (1994) 147-51.
[9] A. Degroot, S. Kashluba, and D. Treit, Septal GABAergic and hippocampal cholinergic systems modulate anxiety in the plus-maze and shock-probe tests. Pharmacol Biochem Behav 69 (2001) 391-9.
[10] S. Pellow, Anxiolytic and anxiogenic drug effects in a novel test of anxiety: are exploratory models of anxiety in rodents valid? Methods Find Exp Clin Pharmacol 8 (1986) 557-65.
[11] R.J. Rodgers, and N.J. Johnson, Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav 52 (1995) 297-303.
[12] A. Backlund, and T. Moritz, Phylogenetic implications of an expanded valepotriate distribution in the Valerianaceae, Elsevier, 1998, pp. 309- 335.
[13] A. Herrera-Arellano, G. Luna-Villegas, M.L. Cuevas-Uriostegui, L. Alvarez, G. Vargas-Pineda, A. Zamilpa-Alvarez, and J. Tortoriello, Polysomnographic evaluation of the hypnotic effect of Valeriana edulis standardized extract in patients suffering from insomnia, 2001, pp. 695- 9.
[14] S. Pellow, P. Chopin, S.E. File, and M. Briley, Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14 (1985) 149-67.
[15] T. Umezu, Effects of psychoactive drugs in the Vogel conflict test in mice. Jpn J Pharmacol 80 (1999) 111-8.
[16] G. Balderer, and A.A. Borbely, Effect of valerian on human sleep. Psychopharmacology (Berl) 87 (1985) 406-9.
[17] P.J. Houghton, The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 51 (1999) 505-12.
[18] K. Low, F. Crestani, R. Keist, D. Benke, I. Brunig, J.A. Benson, J.M. Fritschy, T. Rulicke, H. Bluethmann, H. Mohler, and U. Rudolph, Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290 (2000) 131-4.
[19] C.S. Yuan, S. Mehendale, Y. Xiao, H.H. Aung, J.T. Xie, and M.K. Ang- Lee, The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg 98 (2004) 353-8, table of contents.
[20] C. Cavadas, I. Araujo, M.D. Cotrim, T. Amaral, A.P. Cunha, T. Macedo, and C.F. Ribeiro, In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain. Arzneimittelforschung 45 (1995) 753-5.
[21] M.S. Santos, F. Ferreira, A.P. Cunha, A.P. Carvalho, and T. Macedo, An aqueous extract of valerian influences the transport of GABA in synaptosomes. Planta Med 60 (1994) 278-9.
[22] M.S. Santos, F. Ferreira, A.P. Cunha, A.P. Carvalho, C.F. Ribeiro, and T. Macedo, Synaptosomal GABA release as influenced by valerian root extract--involvement of the GABA carrier. Arch Int Pharmacodyn Ther 327 (1994) 220-31.
[23] E. Riedel, R. Hansel, and G. Ehrke,
[Inhibition of gamma-Aminobutyric Acid Catabolism by Valerenic Acid Derivatives.]. Planta Med 46 (1982) 219-220.
[24] M. Chebib, and G.A. Johnston, The 'ABC' of GABA receptors: a brief review. Clin Exp Pharmacol Physiol 26 (1999) 937-40.
[25] R. Oksztel, H. Car, and K. Wisniewski, Muscimol changes hypoxiainduced impairment of behavior in rats. Pol J Pharmacol 54 (2002) 423- 31.
[26] A. Plaznik, W. Kostowski, and R. Stefanski, Limbic mechanisms of anxiolytics acting on 5-HT receptors. Pol J Pharmacol 46 (1994) 473-7.
[27] H. Sienkiewicz-Jarosz, J. Szyndler, A.I. Czlonkowska, M. Siemiatkowski, P. Maciejak, A. Wislowska, M. Zienowicz, M. Lehner, D. Turzynska, A. Bidzinski, and A. Plaznik, Rat behavior in two models of anxiety and brain (3H)muscimol binding: pharmacological, correlation, and multifactor analysis. Behav Brain Res 145 (2003) 17-22.
[28] R. Stefanski, W. Palejko, A. Bidzinski, W. Kostowski, and A. Plaznik, Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of midazolam and 5-HT1A receptor agonists. Neuropharmacology 32 (1993) 977-85.